Comparative Pharmacology
Head-to-head clinical analysis: ASHLYNA versus INCASSIA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASHLYNA versus INCASSIA.
ASHLYNA vs INCASSIA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ASHLYNA is a combination of ethinyl estradiol and drospirenone. The contraceptive effect is based on inhibition of ovulation and alterations in cervical mucus and endometrial receptivity. Drospirenone has antimineralocorticoid and antiandrogenic activity.
INCASSIA (bleomycin) is an antineoplastic antibiotic that causes DNA strand breaks through free radical generation, inhibiting DNA synthesis and cell division.
One tablet (0.02 mg ethinyl estradiol / 3 mg drospirenone) orally once daily for 21 days, followed by 7 placebo tablets.
1.5 mg orally once daily, administered with or without food.
None Documented
None Documented
Terminal half-life: 12–15 hours; clinical context: supports once-daily dosing
Terminal elimination half-life is 8-12 hours in adults with normal renal function. This supports twice-daily dosing, though dose adjustment is required in renal impairment (CrCl <30 mL/min).
Renal: ~60% unchanged; fecal: ~30% (metabolites); biliary: ~10%
Renal excretion of unchanged drug accounts for approximately 60-70% of the administered dose, with biliary/fecal elimination contributing about 20-30%. Less than 10% is metabolized.
Category C
Category C
Contraceptive
Contraceptive